This company listing is no longer active
ASAP Stock Overview
A biotech company, researches and develops pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Asarina Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.028 |
| 52 Week High | SEK 1.32 |
| 52 Week Low | SEK 0.028 |
| Beta | 0.17 |
| 1 Month Change | -70.83% |
| 3 Month Change | -95.56% |
| 1 Year Change | -96.77% |
| 3 Year Change | -98.86% |
| 5 Year Change | -99.88% |
| Change since IPO | -99.92% |
Recent News & Updates
Shareholder Returns
| ASAP | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -39.9% | 6.4% | 2.8% |
| 1Y | -96.8% | 17.7% | 14.9% |
Return vs Industry: ASAP underperformed the Swedish Pharmaceuticals industry which returned 68.2% over the past year.
Return vs Market: ASAP underperformed the Swedish Market which returned 25.1% over the past year.
Price Volatility
| ASAP volatility | |
|---|---|
| ASAP Average Weekly Movement | 28.5% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in SE Market | 12.0% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: ASAP's share price has been volatile over the past 3 months.
Volatility Over Time: ASAP's weekly volatility has increased from 18% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 6 | Peter Nordkild | www.asarinapharma.com |
Asarina Pharma AB (publ), a biotech company, researches and develops pharmaceutical products. Its’s product is Sepranolone, which is used for the treatment of allopregnanolone-induced stress- and compulsivity-driven disorders from Tourette syndrome to Obsessivecompulsive disorder syndrome. The company was formerly known as Umecrine Mood AB and changed its name to Asarina Pharma AB (publ) in 2016.
Asarina Pharma AB (publ) Fundamentals Summary
| ASAP fundamental statistics | |
|---|---|
| Market cap | SEK 633.96k |
| Earnings (TTM) | -SEK 12.83m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs ASAP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASAP income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 12.83m |
| Earnings | -SEK 12.83m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.57 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 60.6% |
How did ASAP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/10/03 07:35 |
| End of Day Share Price | 2024/10/01 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Asarina Pharma AB (publ) is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ole-Andreas Krohn | DNB Markets |
| Patrik Ling | DNB Markets |
| Anders Hedlund | Redeye |